SpineX Closes Recruitment for SCONE™ Clinical Trial
SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
- SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
- The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
- “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
- SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.